Oncology News | pharmaphorum

News

Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

News

ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.

News

Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."

News

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

News

Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.